Visual Abstract: Ensartinib vs Crizotinib for Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, SEPTEMBER 2, 2021

Media advisory: The full study and editorial are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.3523?guestAccessKey=7cd645db-d6d0-45a4-9410-6c64a6b47b0c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090221

 

Visual Abstract

 

Authors: Leora Horn, M.D., M.S., of Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, and Yi-Long Wu, M.D., of the Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences in Guangzhou, China, are the corresponding authors.

(doi:10.1001/jamaoncol.2021.3523)

Editor’s Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.